Coenzyme Q10 tablet and preparation method thereof
By mixing hydrophilic polyhydroxy polymer skeleton materials with wetting agents, Coenzyme Q10 skeleton complexes, and granulation and tableting with other components, the problems of Coenzyme Q10 dust explosion and stability are solved, and efficient Release and chemical stability are improved, suitable for industrial applications.
Patent Information
- Application Number
- CN202410996712.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
AI Technical Summary
Coenzyme Q10 has safety hazards for dust explosion during the production process, and its chemical stability and release stability are insufficient, which is difficult to effectively solve the problem in the existing technology.
The hydrophilic polyhydroxy polymer skeleton material is mixed with a wetting agent, and Coenzyme Q10 is added to prepare the Coenzyme Q10 skeleton complex, and is granulated and tableted with fillers, disintegrants and lubricants to improve its release degree and chemical stability.
It effectively solves the risk of Coenzyme Q10 dust explosion, improves its release degree and chemical stability, enhances the release stability during the storage of the preparation, and has a simple process and a high safety factor, which is suitable for industrial promotion.
Smart Images

Figure CN118903028A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and particularly relates to a coenzyme Q10 tablet and a preparation method thereof. Background Art
[0002] Coenzyme Q10 is an essential component of tissues with active energy metabolism in the human body. It is mainly distributed in the mitochondria of cells. It can increase myocardial ATP levels, reduce calcium ion loss, stabilize cell membranes and maintain the integrity of calcium ion channels. At the same time, coenzyme Q10 can remove free radicals in the body, so it is also called a natural antioxidant and free radical scavenger. Coenzyme Q10 can reduce the weakening of myocardial contractility and the reduction of creatine phosphate and adenosine triphosphate content during acute ischemia, maintain the morphological structure of ischemic myocardial cell mitochondria, and have a certain protective effect on ischemic myocardium; increase cardiac output, reduce peripheral resistance, and facilitate anti-heart failure treatment.
[0003] Studies have shown that coenzyme Q10 easily absorbs static electricity and may form an explosive mixture when mixed with air. It is highly likely to be ignited. Appropriate safety measures need to be taken during actual application to prevent static electricity from releasing more than the specified energy and causing an explosion.
[0004] Chinese patent application CN109953967A discloses a process study of coenzyme Q10 tablets, which uses an enteric film premix as a coating agent for coenzyme Q10 tablets to obtain coenzyme Q10 tablets with high release, but does not consider its chemical stability and release stability.
[0005] US patent application US4325942A discloses an absorption-enhanced coenzyme Q10 composition, which uses a lipophilic surfactant to increase the absorption of coenzyme Q10 by lymphatic vessels. However, the surfactant is added to the preparation, and the release rate of the product will become lower and lower over time.
[0006] In summary, the chemical stability of coenzyme Q10 and the release stability of the preparation in the prior art need to be improved, and there is also a safety hazard of dust explosion. Summary of the invention
[0007] In order to solve at least some of the problems in the above-mentioned prior art, the present invention adopts a hydrophilic polyhydroxy polymer skeleton material to prepare a coenzyme Q10 skeleton complex, solves the problem of dust explosion during the production and use of coenzyme Q10, and at the same time improves the release degree of coenzyme Q10, enhances the chemical stability of coenzyme Q10 and the release stability during the storage of the preparation. Specifically, the present invention includes the following contents.
[0008] The first aspect of the present invention provides a method for preparing a coenzyme Q10 tablet, comprising the following steps:
[0009] (1) mixing a hydrophilic polyhydroxy polymer skeleton material with a wetting agent, adding coenzyme Q10, and dispersing them evenly to obtain a coenzyme Q10 skeleton complex;
[0010] (2) mixing the coenzyme Q10 skeleton complex with a filler and granulating the mixture to obtain coenzyme Q10 particles;
[0011] (3) The coenzyme Q10 particles are granulated with a disintegrant and a lubricant and then tableted.
[0012] In certain embodiments, according to the method for preparing the coenzyme Q10 tablet of the present invention, the weight ratio of the coenzyme Q10, the hydrophilic polyhydroxy polymer skeleton material and the wetting agent is 1:(0.1-2):(5-20).
[0013] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the hydrophilic polyhydroxy polymer skeleton material includes at least one of hydroxypropyl methylcellulose, hydroxypropyl cellulose and povidone.
[0014] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the wetting agent includes at least one of purified water, high-purity water, ultrapure water, distilled water and deionized water.
[0015] In certain embodiments, according to the method for preparing a coenzyme Q10 tablet of the present invention, the filler comprises at least one of microcrystalline cellulose, carnauba wax, lactose, corn starch, sucrose and dextrin.
[0016] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the disintegrant comprises at least one of carboxymethylcellulose calcium, cross-linked polyvinylpyrrolidone and sodium starch glycolate.
[0017] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the lubricant comprises at least one of silicon dioxide, talc, stearic acid, magnesium stearate and hydrogenated castor oil.
[0018] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the raw materials used include: 5-20 parts by weight of coenzyme Q10, 1-90 parts by weight of filler, 1-10 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 0.1-5 parts by weight of lubricant, 0.1-5 parts by weight of disintegrant and 50-200 parts by weight of wetting agent.
[0019] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the raw materials used include: 10-15 parts by weight of coenzyme Q10, 10-80 parts by weight of filler, 3-8 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 1-3 parts by weight of lubricant, 1-3 parts by weight of disintegrant and 100-150 parts by weight of wetting agent.
[0020] In certain embodiments, according to the method for preparing coenzyme Q10 tablets of the present invention, the raw materials used include: 10 parts by weight of coenzyme Q10, 80 parts by weight of filler, 7 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 2 parts by weight of lubricant, 1 part by weight of disintegrant and 100 parts by weight of wetting agent.
[0021] The second aspect of the present invention provides a coenzyme Q10 tablet, which is prepared by the preparation method of the present invention.
[0022] In certain embodiments, the coenzyme Q10 tablet according to the present invention comprises 5-20 parts by weight of coenzyme Q10, 1-90 parts by weight of a filler, 1-10 parts by weight of a hydrophilic polyhydroxy polymer skeleton material, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a disintegrant.
[0023] In certain embodiments, the coenzyme Q10 tablet according to the present invention comprises 10-15 parts by weight of coenzyme Q10, 10-80 parts by weight of a filler, 3-8 parts by weight of a hydrophilic polyhydroxy polymer skeleton material, 1-3 parts by weight of a lubricant and 1-3 parts by weight of a disintegrant.
[0024] In certain embodiments, the coenzyme Q10 tablet according to the present invention comprises 10 parts by weight of coenzyme Q10, 80 parts by weight of filler, 7 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 2 parts by weight of lubricant and 1 part by weight of disintegrant.
[0025] The preparation method of the present invention can solve the problem of dust explosion during the production and use of coenzyme Q10, and at the same time improve the release degree of coenzyme Q10, enhance the chemical stability of coenzyme Q10 and the release stability during the storage of the preparation. In addition, the preparation method of the present invention is simple and easy to implement, has a stable process, a high safety factor, and a high production efficiency, and can be industrially promoted and applied. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 1 is the dissolution curve of the coenzyme Q10 tablets in the examples and comparative examples.
[0027] Figure 2 This is the dissolution curve of the coenzyme Q10 tablet accelerated for 6 months in the example.
[0028] Figure 3 This is the dissolution curve of the original preparation in Comparative Example 1 after 6 months of accelerated release.
[0029] Figure 4 This is the dissolution curve of the coenzyme Q10 tablets in Comparative Example 2 after 6 months of acceleration. DETAILED DESCRIPTION
[0030] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0031] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that the upper and lower limits of the scope and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0032] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which the invention belongs. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0033] Preparation method
[0034] One aspect of the present invention provides a method for preparing a coenzyme Q10 tablet, comprising the following steps:
[0035] (1) mixing a hydrophilic polyhydroxy polymer skeleton material with a wetting agent, adding coenzyme Q10, and dispersing them evenly to obtain a coenzyme Q10 skeleton complex;
[0036] (2) mixing the coenzyme Q10 skeleton complex with a filler and granulating the mixture to obtain coenzyme Q10 particles;
[0037] (3) The coenzyme Q10 particles are granulated with a disintegrant and a lubricant and then tableted.
[0038] In a preferred embodiment, the preparation method of the present invention comprises the following steps:
[0039] (1) mixing a hydrophilic polyhydroxy polymer skeleton material and a wetting agent, adding coenzyme Q10, and stirring to disperse uniformly to obtain a coenzyme Q10 skeleton complex;
[0040] (2) mixing the coenzyme Q10 skeleton complex with a filler, granulating, and drying to obtain coenzyme Q10 dry particles;
[0041] (3) The coenzyme Q10 dry particles are granulated, mixed with a disintegrant and a lubricant, and tableted.
[0042] Step (1) of the present invention is a step of dissolving a hydrophilic polyhydroxy polymer skeleton material in a wetting agent and dispersing coenzyme Q10 in the dissolved solution. In order to obtain excellent performance, such as but not limited to release degree, chemical stability of coenzyme Q10 and release stability during storage of the preparation, the addition ratio of coenzyme Q10, hydrophilic polyhydroxy polymer skeleton material and wetting agent in step (1) should not be too large or too small.In a preferred embodiment, the weight ratio of the coenzyme Q10, the hydrophilic polyhydroxy polymer skeleton material and the wetting agent is 1: (0.1-2): (5-20), preferably 1: (0.2-1.8): (6-18), further preferably 1: (0.3-1.6): (7-16), and further preferably 1: (0.4-1.4): (8-15), for example 1: 0.4: 8, 1: 0.4: 9, 1: 0.4: 10, 1: 0.4: 11, 1: 0.4: 12, 1: 0.4: 13, 1: 0.4: 14, 1: 0.4: 15, 1: 0.5: 8, 1: 0.5: 9, 1: 0.5: 10、1:0.5:11、1:0.5:12、1:0.5:13、1:0.5:14、1:0.5:15、1:0.6:8、1:0.6:9、1:0.6:10、1:0.6:11、1:0.6:12、1:0.6:13、1:0.6:14、1:0.6:15、1:0.7:8、1:0.7:9、1:0.7:10、1:0.7:11、1:0.7:12、1:0.7:13、1:0.7:14、1:0.7:15、1:0.8:8、1:0.8:9、1:0.8:10、1:0.8:11 , 1:0.8:12, 1:0.8:13, 1:0.8:14, 1:0.8:15, 1:0.9:8, 1:0.9:9, 1:0.9:10, 1:0.9:11, 1:0.9:12, 1:0.9:13, 1:0.9:14, 1:0.9:15, 1:1:8, 1:1:9, 1:1:10, 1:1:11, 1:1:12, 1:1:13, 1:1:14, 1:1:15, 1:1.1:8, 1:1.1:9, 1:1.1:10, 1:1.1:11, 1:1.1:12, 1:1.1:13, 1:1.1:1 4, 1:1.1:15, 1:1.2:8, 1:1.2:9, 1:1.2:10, 1:1.2:11, 1:1.2:12, 1:1.2:13, 1:1.2:14, 1:1.2:15, 1:1.3:8, 1:1.3:9, 1:1.3:10, 1:1.3:11, 1:1.3:12, 1:1.3:13, 1:1.3:14, 1:1.3:15, 1:1.4:8, 1:1.4:9, 1:1.4:10, 1:1.4:11, 1:1.4:12, 1:1.4:13, 1:1.4:14, 1:1.4:15.
[0043] In the present invention, the hydrophilic polyhydroxy polymer skeleton material includes at least one of hydroxypropyl methylcellulose, hydroxypropyl cellulose and povidone or any combination thereof. In a preferred embodiment, the hydrophilic polyhydroxy polymer skeleton material is hydroxypropyl cellulose.
[0044] In the present invention, the wetting agent includes at least one of purified water, high-purity water, ultrapure water, distilled water and deionized water or any combination thereof. In a preferred embodiment, the wetting agent is purified water.
[0045] Step (2) of the present invention is a step of granulation and drying. It should be noted that the tablet dosage form prepared by the present invention does not require coating and is a one-step granulation. Granulation is carried out using equipment known in the art, such as a wet granulator. Drying can be carried out using a drying method or equipment known in the art, which is not particularly limited. In a preferred embodiment, the wet granules are added to a fluidized bed for drying. The parameters for drying are not particularly limited, and suitable drying parameters are selected so that the wetting agent content in the dried dry granules is less than 3%, preferably less than 2%, and further preferably less than 1%, and further preferably less than 0.05%, for example, less than 0.04%, 0.03%, 0.02%, 0.01%, or even does not contain any wetting agent.
[0046] In the present invention, granulation, mixing and tableting can be performed using equipment known in the art, such as a granulator, a mixing barrel and a tablet press to perform corresponding operations.
[0047] In the present invention, the filler includes at least one of microcrystalline cellulose, carnauba wax, lactose, corn starch, sucrose and dextrin or any combination thereof. In a preferred embodiment, the filler is microcrystalline cellulose, carnauba wax, lactose and corn starch.
[0048] In the present invention, the disintegrant includes at least one of carboxymethylcellulose calcium, cross-linked polyvinylpyrrolidone and sodium carboxymethyl starch or any combination thereof. In a preferred embodiment, the disintegrant is carboxymethylcellulose calcium.
[0049] In the present invention, the lubricant comprises at least one of silicon dioxide, talc, stearic acid, magnesium stearate and hydrogenated castor oil or any combination thereof. In a preferred embodiment, the lubricant is silicon dioxide and stearic acid.
[0050] In a preferred embodiment of the preparation method of the present invention, the raw materials of the present invention include: 5-20 parts by weight, preferably 5-15 parts by weight, preferably 6-14 parts by weight, and preferably 7-13 parts by weight, such as 7, 8, 9, 10, 11, 12, and 13 parts by weight of coenzyme Q10; 1-90 parts by weight, preferably 20-90 parts by weight, and preferably 20-88 parts by weight, and further preferably 50-87 parts by weight, more preferably 75-86 parts by weight, and more preferably 75-85 parts by weight, such as 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, and 85 parts by weight of filler; 4-10 parts by weight, preferably 5-9 parts by weight, such as 5, 6, 7, 8, and 9 parts by weight of hydrophilic polyhydroxy polymer skeleton material; 0.1-5 parts by weight, preferably 0.2- 4.5 parts by weight, preferably 0.3-4 parts by weight, for example 0.3, 0.5, 0.8, 1, 1.2, 1.5, 1.7, 2, 2.2, 2.5, 3, 3.2, 3.7, 4 parts by weight of lubricant; 0.1-3 parts by weight, preferably 0.2-2.8 parts by weight, preferably 0.3-2.6 parts by weight, more preferably 0.5-2.4 parts by weight, for example 0.5, 0.8 , 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4 parts by weight of a disintegrant; and 50-200 parts by weight, preferably 60-180, also preferably 80-150, further preferably 100-150 parts by weight, for example 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150 parts by weight of a wetting agent.
[0051] In a preferred embodiment of the preparation method of the present invention, the raw materials of the present invention include: 10 parts by weight of coenzyme Q10, 80 parts by weight of filler, 7 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 2 parts by weight of lubricant, 1 part by weight of disintegrant and 100 parts by weight of wetting agent.
[0052] Coenzyme Q10 Tablets
[0053] One aspect of the present invention provides a coenzyme Q10 tablet, which is prepared by the preparation method of the present invention.
[0054] In a preferred embodiment of the coenzyme Q10 tablet of the present invention, the coenzyme Q10 tablet of the present invention comprises: 5-20 parts by weight, preferably 5-15 parts by weight, further preferably 6-14 parts by weight, further preferably 7-13 parts by weight, for example 7, 8, 9, 10, 11, 12, 13 parts by weight of coenzyme Q10; 1-90 parts by weight, preferably 20-90 parts by weight, further preferably 20-88 parts by weight, further preferably 50-87 parts by weight, more preferably 75-86 parts by weight, more preferably 75-85 parts by weight, for example 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 parts by weight of filler; 4-10 parts by weight , preferably 5-9 weight parts, for example 5, 6, 7, 8, 9 weight parts of hydrophilic polyhydroxy polymer skeleton material; 0.1-5 weight parts, preferably 0.2-4.5 weight parts, also preferably 0.3-4 weight parts, for example 0.3, 0.5, 0.8, 1, 1.2, 1.5, 1.7, 2, 2.2, 2.5, 3, 3.2, 3.7, 4 weight parts of lubricant; 0.1-3 weight parts, preferably 0.2-2.8 weight parts, also preferably 0.3-2.6 weight parts, more preferably 0.5-2.4 weight parts, for example 0.5, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4 weight parts of disintegrant.
[0055] In a preferred embodiment of the coenzyme Q10 tablet of the present invention, the coenzyme Q10 tablet of the present invention comprises: 10 parts by weight of coenzyme Q10, 80 parts by weight of filler, 7 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 2 parts by weight of lubricant and 1 part by weight of disintegrant.
[0056] Example
[0057] The composition and preparation process of Coenzyme Q10 tablets are shown below.
[0058] 1. Composition of Coenzyme Q10 Tablets
[0059] The composition of Coenzyme Q10 tablets is shown in Table 1.
[0060] Table 1 Composition of Coenzyme Q10 tablets
[0061]
[0062] 2. Preparation process
[0063] (1) Preparation of coenzyme Q10 skeleton complex: Dissolve hydroxypropyl cellulose in purified water, add coenzyme Q10, and stir to make it evenly dispersed.
[0064] (2) Granulation: Add carnauba wax, microcrystalline cellulose, lactose, and corn starch into a fluidized bed, add coenzyme Q10 backbone complex, set process parameters, granulate, and dry.
[0065] (3) Granulation: The dry granules are granulated with silicon dioxide, carboxymethylcellulose calcium and stearic acid.
[0066] (4) Mixing: Add the whole granular material into the mixing bucket and mix.
[0067] (5) Tableting.
[0068] Comparative Example 1
[0069] The coenzyme Q10 preparation in this comparative example is the original preparation (Neuquinon) from E-Za Co., Ltd. in the "Catalogue of Generic Drug Reference Preparations" (the 66th batch).
[0070] Comparative Example 2
[0071] The composition and wet granulation process of Coenzyme Q10 tablets are shown below.
[0072] 1. Composition of Coenzyme Q10 Tablets
[0073] The composition of coenzyme Q10 tablets is shown in Table 2.
[0074] Table 2 Composition of Coenzyme Q10 tablets
[0075]
[0076] 2. Preparation process
[0077] (1) Granulation: Add carnauba wax, microcrystalline cellulose, lactose, corn starch, hydroxypropyl cellulose and coenzyme Q10 into a wet granulator, add purified water, set process parameters, and granulate.
[0078] (2) Drying: Add the wet granules into the fluidized bed, set the process parameters, and dry.
[0079] (3) Granulation: The dry granules are granulated with silicon dioxide, carboxymethylcellulose calcium and stearic acid.
[0080] (4) Mixing: Add the whole granular material into the mixing bucket and mix.
[0081] (5) Tableting.
[0082] Verification Example
[0083] 1. Determination of minimum ignition energy (MIE) of dust cloud
[0084] Test method: ASTM E2019-03 Standard test method for minimum ignition energy of dust clouds in air.
[0085] The coenzyme Q10 bulk drug, coenzyme Q10 tablets and granules (Comparative Example 2), and coenzyme Q10 tablets and granules (Example) were tested for MIE according to the detection method, and the results are as follows.
[0086] Table 3 MIE measurement data of each sample
[0087] sample result Coenzyme Q10 API MIE<1mJ Coenzyme Q10 tablets (Comparative Example 2) 30mJ<MIE<50mJ Coenzyme Q10 tablets and granules (Example) 2000mJ<MIE
[0088] By analyzing the above samples, according to the dust electrostatic hazard assessment standard:
[0089] The MIE electrostatic hazard assessment of coenzyme Q10 raw materials is "Level 7". The dust can be easily ignited by static electricity release, and the risk of explosion is very high.
[0090] The electrostatic hazard assessment of the MIE of the coenzyme Q10 tablet particles (Comparative Example 2) is "Level 3". The dust can be ignited by electrostatic discharge. Appropriate safety measures need to be taken to avoid the occurrence of explosion accidents caused by electrostatic discharge exceeding the specified energy.
[0091] The electrostatic hazard assessment of the MIE of the coenzyme Q10 tablet particles (example) is "Level 1", and the possibility of dust being ignited by static electricity release is very small, and the potential explosion risk is very low.
[0092] The results show that the coenzyme Q10 tablets and the preparation method thereof provided in the examples can effectively reduce or even eliminate the risk of coenzyme Q10 dust explosion, and ensure personal safety during the production and use of coenzyme Q10.
[0093] 2. Release degree detection
[0094] Detection method:
[0095] The paddle method was used, with pH 4.0 + surfactant as the dissolution medium, a medium volume of 1000 ml, a rotation speed of 100 revolutions per minute, and 2 ml of the solution was taken as the test solution at 15, 30, 60, 120, and 240 minutes respectively. The cumulative dissolution amount (%) of the coenzyme Q10 tablets was determined and calculated according to the high performance liquid chromatography method (General Rule 0512). The results are as follows.
[0096] Table 4 Dissolution data of examples and original preparations
[0097]
[0098] By analyzing the above samples:
[0099] The dissolution amount of the example in pH 4.0+surfactant medium within 240 min is 92.7%.
[0100] The dissolution amount of Comparative Example 1 (original preparation) in pH 4.0+surfactant medium within 240 min was 86.4%.
[0101] The dissolution amount of Comparative Example 2 in pH 4.0+surfactant medium within 240 min was 77.1%.
[0102] The dissolution amount of the example in the pH 4.0+surfactant medium within 240 minutes is greater than that of comparative example 1 (original preparation) and comparative example 2, indicating that the coenzyme Q10 tablet provided by the example has a higher release rate.
[0103] 3. Release stability test
[0104] The accelerated test was carried out in a constant temperature and humidity environment with high temperature (40°C) and high humidity (relative humidity 75±5%) for 6 months. The dissolution curve was tested after 6 months. The results are as follows.
[0105] Table 5 Dissolution data of coenzyme Q10 tablets accelerated for 6 months in the example
[0106]
[0107] Table 6 Dissolution data of the original preparation in comparative example 1 accelerated for 6 months
[0108]
[0109] Table 7 Dissolution data of coenzyme Q10 tablets accelerated for 6 months in comparative example 2
[0110]
[0111] By analyzing the above samples:
[0112] The dissolution curve of the embodiment placed under accelerated conditions for 6 months showed no significant change compared with that at day 0.
[0113] The dissolution curve of Comparative Example 1 (original preparation) under accelerated conditions for 6 months decreased by about 2-4% compared with that at day 0.
[0114] The dissolution curve of Comparative Example 2 under accelerated conditions for 6 months decreased by about 6-9% compared with that at day 0.
[0115] This indicates that the coenzyme Q10 tablets provided in the embodiment have better release stability when placed under accelerated conditions for 6 months.
[0116] 4. Related substances testing:
[0117] Determine according to the high performance liquid chromatography method (General Rule 0512) and operate in the dark.
[0118] Test solution: Take 20 tablets of this product, accurately weigh, grind, accurately weigh an appropriate amount (equivalent to 20 mg of coenzyme Q10), add an appropriate amount of anhydrous ethanol, shake in a 50°C water bath to dissolve, cool, transfer to a 100 ml volumetric flask, dilute to the scale with anhydrous ethanol, shake well, take the above solution, place in a stoppered centrifuge tube, centrifuge at 3000 rpm for 5 minutes, and take the supernatant.
[0119] Control solution: Accurately measure 1 ml of the test solution, place it in a 100 ml volumetric flask, dilute to the mark with anhydrous ethanol, and shake well.
[0120] Sensitivity solution: Accurately measure 1 ml of the control solution, place it in a 20 ml volumetric flask, dilute to the scale with anhydrous ethanol, and shake well.
[0121] Limits: If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.2 times (0.2%) the area of the main peak of the control solution, and the sum of the areas of all impurity peaks shall not be greater than the main peak area of the control solution (1.0%). Peaks smaller than the main peak area of the sensitivity solution shall be ignored.
[0122] Accelerated test related substances detection:
[0123] The product was placed in a constant temperature and humidity environment with high temperature (40°C) and high humidity (relative humidity 75±5%) for accelerated testing for 6 months. The relevant substances were detected during the 6 months. The results are as follows.
[0124] Table 8 Related substance results of Examples and Comparative Examples
[0125]
[0126] By analyzing the above samples:
[0127] The related substances of the examples showed no significant changes during the accelerated 6-month process.
[0128] The related substances of the original preparation in Comparative Example 1 increased during the 6-month accelerated process, and the single impurity exceeded the upper limit, while the total impurity reached the upper limit during the 6-month accelerated process.
[0129] The related substances in Comparative Example 2 increased during the 6-month accelerated process, and the single impurity exceeded the upper limit.
[0130] It can be seen that the related substances in the example are far lower than those in comparative example 1 (original preparation) and comparative example 2, indicating that the coenzyme Q10 tablets provided in the example have better chemical stability.
[0131] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for preparing a coenzyme Q10 tablet, It is characterized in that It includes the following steps: (1) mixing a hydrophilic polyhydroxy polymer skeleton material with a wetting agent, adding coenzyme Q10, and dispersing them evenly to obtain a coenzyme Q10 skeleton complex; (2) mixing the coenzyme Q10 skeleton complex with a filler and granulating the mixture to obtain coenzyme Q10 particles; (3) The coenzyme Q10 particles are granulated with a disintegrant and a lubricant and then tableted.
2. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The weight ratio of the coenzyme Q10, the hydrophilic polyhydroxy polymer skeleton material and the wetting agent is 1:(0.1-2):(5-20).
3. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The hydrophilic polyhydroxy polymer skeleton material includes at least one of hydroxypropyl methylcellulose, hydroxypropyl cellulose and povidone.
4. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The wetting agent includes at least one of purified water, high-purity water, ultrapure water, distilled water and deionized water.
5. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The filler includes at least one of microcrystalline cellulose, carnauba wax, lactose, corn starch, sucrose and dextrin.
6. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The disintegrant comprises at least one of carboxymethylcellulose calcium, cross-linked polyvinylpyrrolidone and sodium starch glycolate.
7. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The lubricant includes at least one of silicon dioxide, talc, stearic acid, magnesium stearate and hydrogenated castor oil.
8. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The raw materials used include: 5-20 parts by weight of coenzyme Q10, 1-90 parts by weight of filler, 1-10 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 0.1-5 parts by weight of lubricant, 0.1-5 parts by weight of disintegrant and 50-200 parts by weight of wetting agent.
9. The method for preparing the coenzyme Q10 tablet according to claim 1, It is characterized in that The raw materials used include: 10-15 parts by weight of coenzyme Q10, 10-80 parts by weight of filler, 3-8 parts by weight of hydrophilic polyhydroxy polymer skeleton material, 1-3 parts by weight of lubricant, 1-3 parts by weight of disintegrant and 100-150 parts by weight of wetting agent.
10. Coenzyme Q10 tablets, It is characterized in that The compound is prepared by the preparation method according to any one of claims 1 to 8.
